Long COVID
Conditions
Keywords
Long COVID, Post-COVID Condition, Post-Acute Sequelae of COVID-19, Brain Fog, Fatigue, Ketamine
Brief summary
Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called "brain fog"). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongoing health issues like tiredness, memory problems, and difficulty concentrating. Right now, there are very few treatments available for these symptoms, and many people are looking for new options to feel better. What is the study trying to find out? Does ketamine help reduce fatigue and improve thinking skills in people with Long COVID? Does ketamine improve overall quality of life and mental health for people with Long COVID? Is ketamine safe and well-tolerated for people with Long COVID? How does ketamine affect the body's biological processes, like inflammation and brain function? How will the study work? The study will include 20 adults between 18 and 65 years old who have Long COVID symptoms like fatigue or brain fog. Participants will first meet with researchers to answer health questions, take surveys about their symptoms, and do tests to check their thinking skills. All participants will also have a brain scan (MRI) and give a blood sample to look at markers of inflammation. Participants will then receive four ketamine treatments over two weeks at a specialized clinic. The ketamine will be given as an injection, with the dose slightly increasing during the treatment period. After six weeks, participants will return for follow-up tests to see if their symptoms have improved. This includes repeating the surveys, thinking tests, MRI and blood test. Why ketamine? Ketamine is a medicine originally used for anesthesia but has also been found to help with depression and other mental health issues. Researchers think it might help with Long COVID symptoms because it can reduce inflammation in the brain and improve how the brain functions. People with Long COVID often have signs of inflammation and changes in brain chemicals, which ketamine might help balance. What are the potential benefits? Participants might experience less fatigue and clearer thinking after ketamine treatment. They could also feel better overall in terms of mood and quality of life. Since ketamine can work quickly, some people may notice improvements shortly after starting the treatment. What are the risks? Ketamine can cause side effects like feeling dizzy, anxious, or having an unusual sense of reality (sometimes called dissociation). It may also cause temporary increases in blood pressure or heart rate. All treatments will be carefully monitored by healthcare professionals to ensure safety. Who can participate? Adults aged 18-65 with Long COVID who have significant fatigue or thinking problems can join. People will not be able to participate if they have certain health conditions like severe heart disease, uncontrolled high blood pressure, or a history of severe mental health disorders. Why is this study important? Long COVID affects millions of people, and many are struggling to find treatments that work. This study is one of the first to explore ketamine as a potential treatment for Long COVID symptoms. If ketamine helps, it could lead to more research and eventually new treatment options for people living with Long COVID.
Interventions
DRUGKetamine only
Participants in this arm will receive four intramuscular (IM) ketamine injections over a two-week period. The initial dose will be 0.5 mg/kg during the first session, increasing to 0.65 mg/kg in the second session, and 0.75 mg/kg for the third and fourth sessions. Injections will be administered at least three days apart.
Sponsors
University of Texas at Austin
Roots Behavioral Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adults aged 18-65 years diagnosed with LC and possess a documented history of positive COVID-19 diagnostic testing or a probable infection as determined by a healthcare provider. * One persistent symptom of fatigue or neurocognitive dysfunction as defined by rating their symptoms as moderate to severe on the screening form. * English as a primary language OR comprehension of English suitable to understand research staff instructions. * All participants must be eligible for MRI and will undergo MRI scans pre- and post-treatment
Exclusion criteria
Contraindications to ketamine therapy: * Current substance use disorder * Current mania or psychosis * Recent myocardial infarction or stroke (within 1 year) * Unstable cardiovascular disease (including uncontrolled high blood pressure \> 180/110 mmHg) * Uncontrolled seizure disorder * Pregnancy Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PROMIS SF v1.0 - Fatigue 8a | At enrollment and at the post-treatment assessment visit, 6 weeks following completion of the ketamine treatment. | A patient-reported questionnaire measuring the severity and impact of fatigue on daily activities over the past 7 days. Higher scores indicate greater fatigue. |
| PROMIS SF v2.0 Cognitive Function 4a | At enrollment and at the post-treatment assessment visit, 6 weeks following completion of the ketamine treatment. | A patient-reported tool that measures perceived cognitive abilities, such as memory, concentration, and mental clarity, over the past 7 days. Higher scores reflect better cognitive function. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PROMIS Global 10 v1.2 | Collected at baseline (pre-treatment) and at the post-treatment assessment (6 weeks after the final ketamine session). | A 10-item questionnaire assessing overall physical, mental, and social health, including pain, fatigue, and emotional well-being. |
| NASA Task Load Index (NASA-TLX) | Collected at baseline (pre-treatment) and at the post-treatment assessment (6 weeks after the final ketamine session). | A tool used to evaluate perceived mental workload, assessing factors like mental demand, effort, and frustration during cognitive tasks like BrainCheck. |
| Patient Health Questionnaire-9 (PHQ-9) | Collected before each ketamine treatment session, at baseline, and at the post-treatment assessment (6 weeks post-treatment). | A widely used self-report measure to assess the severity of depressive symptoms over the past two weeks. |
| Number of participants with treatment-related adverse events as assessed by standardized interview | Adverse events will be assessed at each of the four ketamine treatment sessions and during the final post-treatment assessment, which occurs six weeks after the last ketamine injection. | A standardized interview conducted post-treatment to identify and record any physical or psychological side effects experienced by participants during the ketamine therapy. |
| BrainCheck Cognitive Battery | At enrollment and at the post-treatment assessment visit, 6 weeks following completion of the ketamine treatment. | A computerized series of neuropsychological tests assessing objective cognitive functions, including memory, attention, executive function, processing speed, and response inhibition. Scores are age-normalized. |
| Generalized Anxiety Disorder-7 (GAD-7) | Collected before each ketamine treatment session, at baseline, and at the post-treatment assessment (6 weeks post-treatment). | A widely used 7-item scale measuring the severity of anxiety symptoms over the past two weeks. |
| Depression in Medically Ill 10 Scale (DMI-10) | Collected at baseline (pre-treatment) and at the post-treatment assessment (6 weeks after the final ketamine session). | A measure designed to assess depressive symptoms specifically in individuals with medical conditions, focusing on somatic and cognitive symptoms. |
| Long COVID Review of Systems | Collected at baseline (pre-treatment) and at the post-treatment assessment (6 weeks after the final ketamine session). | A comprehensive symptom checklist adapted from the WHO's Global COVID-19 Clinical Platform, evaluating the range and severity of Long COVID symptoms. |
| Neuroimaging (MRI) Outcomes | Performed at baseline and repeated at the post-treatment assessment (6 weeks after the final ketamine session). | Functional MRI (fMRI) scans will evaluate changes in brain structure and connectivity, providing insight into the neurological effects and mechanisms of ketamine. |
| Serum Biomarker Analysis | Collected at baseline and at the post-treatment assessment (6 weeks after the final ketamine session). | Blood samples will be analyzed for inflammatory and metabolic markers, including cytokines and metabolites in the kynurenine pathway, to assess biological responses to ketamine treatment. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORW. Michael Brode, MD
University of Texas at Austin
Outcome results
None listed